

Editorial

Can the analysis of BH3-only protein knockout mice clarify the issue of ‘direct versus indirect’ activation of Bax and Bak?

A Villunger^{*1}, V Labi¹, P Bouillet^{2,3}, J Adams^{2,3} and A Strasser^{*2,3}

Cell Death and Differentiation (2011) 18, 1545–1546; doi:10.1038/cdd.2011.100

A recent study by Ren *et al.*¹ contributes to the ongoing debate about how interactions between factions of the Bcl-2 protein family provoke apoptosis, but the data presented do not, in our view, support the overall conclusion that ‘Bid, Bim and Puma are essential for activation of the Bax- and Bak-dependent cell death program’.

It is generally accepted that, in response to diverse cellular stresses, the Bcl-2 distant cousins termed ‘BH3-only proteins’, for example, Bim, Bid or Puma, initiate the apoptotic process and that the pivotal step (mitochondrial outer membrane permeabilization) requires the proapoptotic Bcl-2 family members Bak or Bax,² but how the BH3-only proteins provoke activation of Bax and Bak remains controversial. The ‘direct activation’ model³ posits that Bim, Bid and possibly Puma serve as direct ‘activators’. In healthy cells, prosurvival Bcl-2 proteins sequester them, but cytotoxic stimuli upregulate or activate ‘sensitizer BH3-only proteins’ (Bad, Bik, Hrk, Noxa and Bmf) whose binding to the prosurvival Bcl-2 proteins liberates the ‘activators’ to transiently engage and activate Bax/Bak. Conversely, the ‘indirect model’⁴ postulates that in healthy cells a small proportion of Bax and Bak is primed to elicit cell death but sequestered by prosurvival Bcl-2 proteins, and that BH3-only proteins must engage all prosurvival proteins in a given cell to unleash Bax/Bak for death duty. This can either be achieved by Bim, Puma or Bid, which can bind all their prosurvival relatives, or by combinations of BH3-only proteins that bind complementary subsets (e.g., Bad, binding Bcl-2, Bcl-x_L and Bcl-w, plus Noxa, binding Mcl-1 and A1^{4,5}). Although biochemical studies have provided conflicting results, the indirect activation model was supported by the observation that Bax/Bak double-deficient (DKO) mice² have much more severe developmental and apoptotic defects than mice lacking Bim and Bid,⁴ the two most widely accepted ‘direct activators’ within the Bcl-2 family.

Ren *et al.*¹ generated *Bim/Bid/Puma* triple-deficient (TKO) mice to resolve whether Puma also functions as a ‘direct activator’ and to clarify the mechanisms of Bax/Bak activation. They report that triple deficiency for Bim, Bid and Puma

mirrors Bax/Bak double deficiency and argue that this provides proof for the ‘direct activation’ model. This is, however, incorrect. First, there are substantial differences in phenotype between *Bim/Bid/Puma* TKO¹ and *Bax/Bak* DKO mice.² Although *Bax/Bak* DKO mice die perinatally with severe brain abnormalities, no such profound neurological defects and associated perinatal lethality were reported for the *Bim/Bid/Puma* TKO mice. Furthermore, although some interdigital webbing persisted in *Bim/Bid/Puma* TKO mice,¹ it appears less extensive than in *Bax/Bak* DKO mice² or in *Bim*^{-/-}*Bmf*^{-/-} mice⁶ (AV, PB and VL, unpublished), in which webs persist despite the presence of both Bid and Puma. Moreover, the defect in vaginal development in *Bim/Bid/Puma* TKO mice shows incomplete penetrance,¹ but occurs in 100% of *Bax/Bak* DKO mice.² Thus, in a significant portion of *Bim/Bid/Puma* TKO mice, the physiological cell death driven by Bax and/or Bak continues to some extent in multiple tissues.

The reported *in vitro* cell survival assays also fail to unambiguously demonstrate that all induction of apoptosis requires Bid, Bim or Puma. A proportion of the TKO lymphoid cells still died in response to DNA damage or glucocorticoids,¹ whereas *Bax/Bak* DKO cells are fully refractory.² This difference may indicate that these death stimuli activate additional (i.e., non ‘direct activator’) BH3-only proteins that collectively can neutralize the prosurvival Bcl-2 proteins in these cells, thereby leading to Bax/Bak activation, consistent with the ‘indirect model’. Moreover, the role of Bid in the lymphocyte death probably is negligible: although this study failed to provide data on survival of *Bim/Puma* DKO lymphocytes, previous studies^{7,8} have shown that their combined loss renders multiple hematopoietic cell types as resistant to the apoptotic stimuli studied as reported for the *Bim/Bid/Puma* TKO cells.¹

Thus, the phenotype of the TKO mice is less profound than that of *Bax/Bak* DKO animals and does not prove the direct activation model. As the TKO mice lack the three BH3-only proteins that can neutralize all the prosurvival family members,⁵ the observed apoptotic deficiencies are also

¹Division of Developmental Immunology, Biocenter, Innsbruck Medical University, Innsbruck, Austria; ²Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia and ³Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia

*Corresponding authors: A Villunger, Division of Developmental Immunology, Biocenter, Innsbruck Medical University, A-6020 Innsbruck, Austria.

Tel: +43 512 9003 70380; Fax: +43 512 9003 73960; E-mail: andreas.villunger@i-med.ac.at

or A Strasser, Molecular Genetics of Cancer Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Melbourne, 3050 Victoria, Australia.

Tel: +61 3 9345 2624; Fax: +61 3 9347 0852; E-mail: strasser@wehi.edu.au

compatible with the 'indirect model'. Nevertheless, increasing *in vitro* findings, for example,^{9,10} suggest that certain BH3 domains can directly activate Bax, and a recent *in vivo* study using gene-targeted mice in which the BH3 region of Bim has been subtly altered argues that aspects of both models may well hold.¹¹ Most of the seemingly conflicting published results can be reconciled if Bax and Bak can be activated in multiple ways: in some circumstances by Bid, Bim or Puma, but also, albeit perhaps less efficiently, by certain other BH3-only proteins,¹² or by mechanisms independent of BH3-only proteins,³ such as by Bax phosphorylation, heat-induced conformational change, or spontaneous activation after the neutralization or degradation of the restraining prosurvival Bcl-2 proteins, as seen in platelets. As small

molecules that target prosurvival Bcl-2 proteins are showing great clinical promise, it will be essential to understand these mechanisms to achieve optimal killing of tumor cells.

1. Ren D *et al.* *Science (New York, NY)* 2010; **330**: 1390.
2. Lindsten T *et al.* *Mol Cell* 2000; **6**: 1389.
3. Chipuk JE, Green DR. *Trends Cell Biol* 2008; **18**: 157.
4. Willis SN *et al.* *Science (New York, NY)* 2007; **315**: 856.
5. Chen L *et al.* *Mol Cell* 2005; **17**: 393.
6. Hubner A *et al.* *Mol Cell Biol* 2010; **30**: 98.
7. Erlacher M *et al.* *J Exp Med* 2006; **203**: 2939.
8. Karlberg M *et al.* *Cell Death Dis* 2010; **1**: e43.
9. Gavathiotis E *et al.* *Nature* 2008; **455**: 1076.
10. Lovell JF *et al.* *Cell* 2008; **135**: 1074.
11. Merino D *et al.* *J Cell Biol* 2009; **186**: 355.
12. Du H *et al.* *J Biol Chem* 2010; **286**: 491–501.